These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5043471)

  • 1. Study on the influence of dialysis with varying bath calcium concentrations on the different plasma calcium fractions.
    Verberckmoes R
    Klin Wochenschr; 1972 May; 50(9):480-2. PubMed ID: 5043471
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal bone disease.
    Cundy TF; Kanis JA
    Br J Hosp Med; 1985 Jan; 33(1):35-40. PubMed ID: 3882177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 4. [Review on internal medicine, 1984. Electrolyte disturbance. III-3. Renal osteodystrophy].
    Ogura Y
    Nihon Naika Gakkai Zasshi; 1985 Jun; 74(6):726-30. PubMed ID: 4045286
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dialysis bone disease in children. Six cases (author's transl)].
    Luciani JC; Ferran JL; Dumas ML; Meunier P; Dumas R
    Nouv Presse Med; 1977 Nov; 6(39):3616-9. PubMed ID: 607175
    [No Abstract]   [Full Text] [Related]  

  • 6. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis.
    Coburn JW
    Kidney Int Suppl; 1993 Feb; 40():S92-100. PubMed ID: 8445845
    [No Abstract]   [Full Text] [Related]  

  • 7. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. III. Clinical algorithms on renal osteodystrophy.
    Nephrol Dial Transplant; 2000; 15 Suppl 5():39-57. PubMed ID: 11073276
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 10. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 11. Focus on vitamin D therapy in chronic kidney disease.
    Tentori F
    J Nephrol; 2007; 20(5):511-4. PubMed ID: 17918134
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of varying dialysate calcium concentrations on the plasma calcium fractions in patients on dialysis.
    Raman A; Chong YK; Sreenevasan GA
    Nephron; 1976; 16(3):181-7. PubMed ID: 635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arguments justifying the measurement of the most relevant biochemical parameters to monitor bone and mineral metabolism in dialysis patients].
    Ureña Torres PA; Jean G
    Nephrol Ther; 2023 Aug; 19(4):293-296. PubMed ID: 37533272
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 15. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
    Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 17. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 18. [Study on calcium-regulating hormone in patients on chronic hemodialysis with special reference to renal osteodystrophy (ROD) (author's transl)].
    Kudo S
    Nihon Jinzo Gakkai Shi; 1982 Feb; 24(2):181-96. PubMed ID: 7098141
    [No Abstract]   [Full Text] [Related]  

  • 19. Late complications of long-term hemodialysis in children: clinical aspects and some measurable variables concerning parathyroid hormone, divalent ions, acid-base metabolism, anemia, nutrition, growth and survival data.
    Chan JC
    J Urol; 1978 Nov; 120(5):578-85. PubMed ID: 712902
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction in dialysate calcium concentration lowers skin calcium content in patients on chronic hemodialysis.
    Zinn D; Cruz C; Smith D; Potocki M; Parfitt C; Hricak H; Levin NW; Kleerekoper M
    Trans Am Soc Artif Intern Organs; 1980; 26():378-82. PubMed ID: 7245518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.